Embecta reports Q4 EPS (30c), consensus 66c

Reports Q4 revenue $274.6M, consensus $261.01M. "2022 was a milestone year for embecta, our first as a public company," said CEO Devdatt Kurdikar. "We are very proud of our colleagues around the world, whose perseverance, collaboration, and focus led to this performance notwithstanding a dynamic and challenging macro environment. Despite incremental headwinds from foreign exchange and inflation, our Q4 and second half of fiscal year 2022 results exceeded our guidance and advanced our mission to develop and provide solutions that make life better for people living with diabetes. Looking forward, FY23 will be a critical year as we take steps to further strengthen our core business, make additional progress towards separating and standing up embecta as an independent company, and invest in growth opportunities, including the further development of our type 2 closed loop insulin delivery system."